Ayala Pharmaceuticals (NASDAQ:ADXS) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com began coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a research note issued to investors on Monday. The firm set a “sell” rating on the stock.

Ayala Pharmaceuticals Price Performance

Shares of ADXS opened at $0.03 on Monday. Ayala Pharmaceuticals has a 1-year low of $0.00 and a 1-year high of $0.78. The company has a 50-day moving average of $0.03 and a 200 day moving average of $0.04. The firm has a market capitalization of $1.28 million, a price-to-earnings ratio of 0.00 and a beta of 1.68.

Ayala Pharmaceuticals Company Profile

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.